A Phase I/Ib Trial Targeting the Pi3k/Akt Pathway Using Perifosine: Long-term Progression-free Survival of Patients with Resistant Neuroblastoma
Overview
Authors
Affiliations
AKT plays a pivotal role in driving the malignant phenotype of many cancers, including high-risk neuroblastoma (HR-NB). AKT signaling, however, is active in normal tissues, raising concern about excessive toxicity from its suppression. The oral AKT inhibitor perifosine showed tolerable toxicity in adults and in our phase I trial in children with solid tumors (clinicaltrials.gov NCT00776867). We now report on the HR-NB experience. HR-NB patients received perifosine 50-75 mg m day after a loading dose of 100-200 mg m on day 1, and continued on study until progressive disease. The 27 HR-NB patients included three treated for primary refractory disease and 24 with disease resistant to salvage therapy after 1-5 (median 2) relapses; only one had MYCN-amplified HR-NB. Pharmacokinetic studies showed μM concentrations consistent with cytotoxic levels in preclinical models. Nine patients (all MYCN-non-amplified) remained progression-free through 43+ to 74+ (median 54+) months from study entry, including the sole patient to show a complete response and eight patients who had persistence of abnormal I-metaiodobenzylguanidine skeletal uptake but never developed progressive disease. Toxicity was negligible in all 27 patients, even with the prolonged treatment (11-62 months, median 38) in the nine long-term progression-free survivors. The clinical findings (i) confirm the safety of therapeutic serum levels of an AKT inhibitor in children; (ii) support perifosine for MYCN-non-amplified HR-NB as monotherapy after completion of standard treatment or combined with other agents (based on preclinical studies) to maximize antitumor effects; and (iii) highlight the welcome possibility that refractory or relapsed MYCN-non-amplified HR-NB is potentially curable.
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.
Sharma R, Yadav J, Bhat S, Musayev A, Myrzagulova S, Sharma D Mol Neurobiol. 2025; .
PMID: 39804528 DOI: 10.1007/s12035-024-04680-w.
Therapy resistance in neuroblastoma: Mechanisms and reversal strategies.
Zhou X, Wang X, Li N, Guo Y, Yang X, Lei Y Front Pharmacol. 2023; 14:1114295.
PMID: 36874032 PMC: 9978534. DOI: 10.3389/fphar.2023.1114295.
Richardson P, Nagler A, Ben-Yehuda D, Badros A, Hari P, Hajek R EJHaem. 2022; 1(1):94-102.
PMID: 35847734 PMC: 9175725. DOI: 10.1002/jha2.4.
PRMT5 activates AKT via methylation to promote tumor metastasis.
Huang L, Zhang X, Rozen E, Sun X, Sallis B, Verdejo-Torres O Nat Commun. 2022; 13(1):3955.
PMID: 35803962 PMC: 9270419. DOI: 10.1038/s41467-022-31645-1.
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma.
Musumeci F, Cianciusi A, DAgostino I, Grossi G, Carbone A, Schenone S Molecules. 2021; 26(23).
PMID: 34885651 PMC: 8658969. DOI: 10.3390/molecules26237069.